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Anxiety disorders are complex diseases, which often occur in combination with major depression, alcohol use
disorder, or general medical conditions. Anxiety disorders were the most common mental disorders within the EU
states in 2010 with 14% prevalence. Anxiety disorders are triggered by environmental factors in genetically
susceptible individuals, and therefore genetic research offers a great route to unravel molecular basis of these
diseases. As anxiety is an evolutionarily conserved response, mouse models can be used to carry out genome-wide
searches for specific genes in a setting that controls for the environmental factors. In this review, we discuss
translational approaches that aim to bridge results from unbiased genome-wide screens using mouse models to
anxiety disorders in humans. Several methods, such as quantitative trait locus mapping, gene expression profiling,
and proteomics, have been used in various mouse models of anxiety to identify genes that regulate anxiety or play
a role in maintaining pathological anxiety. We first discuss briefly the evolutionary background of anxiety, which
justifies cross-species approaches. We then describe how several genes have been identified through genome-wide
methods in mouse models and subsequently investigated in human anxiety disorder samples as candidate genes.
These studies have led to the identification of completely novel biological pathways that regulate anxiety in mice
and humans, and that can be further investigated as targets for therapy.
Keywords: Anxiety disorders, Anxiety-like behavior, Mouse model, Cross-species approach, Genome-wide
association study, Quantitative trait locus, Gene expression, Proteomics, Candidate geneReview
Anxiety disorders
Anxiety and fear are normal emotional responses to
threatening situations. In anxiety disorders these responses
are exaggerated or prolonged and disturb daily life. Anxiety
disorders, including panic disorder, obsessive-compulsive
disorder (OCD), post-traumatic stress disorder (PTSD),
social phobia, specific phobias, and generalized anxiety
disorder (GAD), were the most common mental disorders
within the EU states in 2010 with 14% prevalence [1].
Anxiety disorders are currently treated with drugs and/or
cognitive behavioral therapy or other psychosocial treat-
ments. Current pharmacotherapeutic options including
benzodiazepines and selective serotonin reuptake inhibitors
are not optimal due to addictive properties, development of
tolerance, or poor efficacy in some patients. Therefore, new* Correspondence: iiris.hovatta@helsinki.fi
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distribution, and reproduction in any mediumand better anxiolytics are needed, and their development
requires understanding of the molecular mechanisms that
regulate anxiety. Genetics offer an ideal route to the
molecular background of anxiety as any identified genes
can directly be linked to their function within the cell and
the neural circuits.
Anxiety disorders are complex diseases caused by a
combination of genetic and environmental factors. In
recent years, several genes have been associated with
anxiety disorders [2]. Replicated associations exist to genes
belonging to various neurotransmitter or neuropeptide
systems [3]. Recently, the first genome-wide association
studies (GWAS) aiming to identify common variants have
been published in anxiety-related personality trait neur-
oticism and panic disorder [4-7]. These studies support
involvement of a relatively large number of small effect size
common and rare variants in the predisposition to anxiety
disorders, a notion shared with other psychiatric diseases,
such as schizophrenia and major depression. Therefore,
very large sample sizes (several thousands of individuals)ed Central Ltd. This is an Open Access article distributed under the terms of
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anxiety disorders.
Anxiety is an evolutionarily conserved response and
can be reliably measured in mice (Table 1). The advantage
of mouse models is that the environmental factors can be
controlled for, or specifically administered. In addition,
brain tissue can be collected at any time point. To comple-
ment human genetic studies several groups have used
mouse models of anxiety-like behavior for identification of
genes and biological pathways that regulate anxiety. In
general two approaches can be taken: i) candidate gene
studies have mostly used transgenic models to investigate
a role of a specific gene in the regulation of anxiety, and ii)
genome-wide approaches do not make any prior assump-
tions regarding which genes contribute to the phenotype.
In this review, we will concentrate on genome-wide ap-
proaches in mice, which have resulted in the identification
of genes regulating anxiety. We have further restricted our
focus to those genes that have subsequently been associated
at some level to human anxiety disorders. Therefore, sev-
eral interesting genes that may regulate anxiety but i) have
been identified initially through transgenic mouse models,
ii) human candidate gene or GWAS studies, or iii) have
been identified in mouse models but not shown any link to
human anxiety disorders, are not discussed here [8-10].
Anxiety is an evolutionarily conserved response
Why can we use the mouse to model aspects of human
anxiety disorders? Neuroevolutionary studies have
shown that anxiety is an adaptive response that has been
conserved during evolution [12,13]. From this perspective
anxiety is viewed as a behavioral state, which occurs in
response to signals of danger. On the physiological level
these signals initiate activation of the hypothalamus-
pituitary-adrenal (HPA) axis [14] and secretion of adrenal
steroids called stress hormones, which are present in almost
every vertebrate cell [15]. This leads to increased heart rate,Table 1 Comparison of human anxiety disorders to anxiety-li
Disorder Human symptoms
Generalized anxiety disorder Excessive worry about everyday life,
leading to difficulties in concentration
Posttraumatic stress disorder Repeated re-experiencing traumatic events,
leading to avoidance of stimuli associated
with trauma
Obsessive-compulsive disorder Intrusive thoughts that produce repetitive
behavior aimed at reducing anxiety
Social phobia avoidance of social contact, emotional
discomfort caused by presence of
unknown people
Panic disorder Intense fearfulness of sudden onset,
respiratory distress
Agoraphobia Avoidance of wide-open or crowded space
Anxiety disorders are classified according to the Diagnostic and Statistical Manual o
test; L/D, Light/dark box test. Modified from [11].deeper breathing, vigilance, decrease in feeding, and explor-
ation of environment [16]. The genes that code for stress
hormones are highly conserved across diverse species:
primates, rodents, reptiles, and amphibians [17,18].
Mice represent a good model system for human anxiety
disorders for several reasons: i) they have a central nervous
system (CNS) that is sufficiently developed to model
aspects of human anxiety as compared to lower organisms,
ii) hundreds of inbred strains are available, and the whole
genome sequence of 17 strains has been determined [19],
iii) transgenic techniques to manipulate the genome are
well established, and iv) their maintenance is cost-effective.
The majority of the anxiety-related behavioral tests utilize
approach-avoidance behaviors that appear to mirror ro-
dent’s behavioral response to conflict in its natural environ-
ment. Both approach behaviors, such as mate searching
and foraging, and avoidance behaviors, such as escape from
the predator, are evolutionarily conserved in some forms
from nematodes to mammals [20]. Furthermore, the neural
organization of behaviors underlying fearful, sexual,
feeding, and escape motivation is relatively similar across
species [21]. Disturbed balance in approach-avoidance
behaviors is a symptom of autism [22], PTSD [23], and
social phobia [24]. Several paradigms to test anxiety in
mice, based on the approach-avoidance behavior, have been
developed and pharmacologically validated with drugs that
are used to treat human disease and are therefore consid-
ered appropriate models for human anxiety [25]. The most
commonly used tests include the elevated plus maze, open
field, light dark box, and novelty-induced hypophagia tests.
In these tests mice have to choose between exploring and
staying in a safe environment. However, due to cognitive
differences between mouse and human, it is recognized that
no animal model can mimic all aspects of human anxiety
and anxiety disorders. Nevertheless, genes that regulate
anxiety in mice are excellent candidate genes for anxiety
disorders (Figure 1).ke behavior in mice
Observed behavior in mice Behavioral test in mice
Decreased social interaction, impaired
sustained attention
OF, L/D, Y-maze
Increased freezing response to fear
conditioning, decreased fear extinction,
more pronounced spontaneous recovery
Cue and contextual fear
conditioning, fear extinction




Low social interaction Three-chamber test of sociability,
social recognition test
Increased escape from an aggressor Resident intruder test
Avoidance of exposed, bright areas OF, L/D
f Mental Disorders of American Psychiatric Association (DSM-IV). OF, Open field
Figure 1 A strategy for a cross-species mouse and human genetic approach to identify susceptibility genes for anxiety disorders. The
greatest advantages of using mouse models are the ability to reduce genetic heterogeneity and to control for the environment. The first step is
to characterize aspects of a human disease in a mouse model, and to perform a search for candidate genes in a mouse model. It is then
important to study these candidates in human populations to determine if they predispose to the disease under study. Mouse models are,
however, needed to further characterize the function of the candidate genes, and to carry out potential drug target validation. Examples of
candidate genes identified using different approaches in mice and humans are shown. Modified from [2].
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QTL mapping has been used to identify genes that
regulate anxiety-like behavior in rodents [26], with the idea
that genes in the homologous loci in humans can then be
studied as susceptibility genes for the corresponding human
phenotype. Traditionally, QTL mapping has been based on
genotyping F2 mice using a genome-wide marker panel
and measuring the anxiety level of these animals. As a
result, loci that likely contain genes affecting the
phenotype can be mapped. Due to the low mapping
resolution of F2 panels, other sources, such as recombinant
inbred strains, heterogeneous stock mice, and outbred
animals, have been used for initial and fine mapping
[27-29]. It is expected that the Collaborative Cross strains,
a collection of recombinant inbred mouse strains derived
from eight parental strains, will be an efficient mapping
resource in the future to identify both major loci and their
modifiers [30]. Although initial enthusiasm for QTL
mapping has been suppressed by low efficiency and
resolution, and small effect size of individual variants,
several anxiety-associated genes have been identified
through QTL mapping [31-37]. Here we will discuss
those genes that have shown some evidence for associationto human anxiety disorders in subsequent studies. These
include Gad2, Rgs2, Ppargc1a, Gabra2, Oprm1, and TrkB.
Glutamic acid decarboxylase 2 (Gad2)
One of the earliest cross-species studies investigated
behavioral inhibition to the unfamiliar, a heritable tem-
perament character that is considered a risk factor for
panic and phobic anxiety [38]. Four genes were selected
for genotyping in humans based on their homology to loci
previously associated with anxiety or fear behavior in
mice. The sample consisted of 72 behaviorally inhibited
children and their family members, analyzed in a family-
based association analysis. Suggestive evidence for associ-
ation was found to variants in the GAD2 gene. GAD2 is
an enzyme involved in the gamma-aminobutyric acid
(GABA) synthesis, and is therefore an intriguing candidate
gene as abnormalities in the GABA system have been
observed in anxiety disorders [39]. GAD2 has been studied
as a candidate gene for anxiety disorders in two larger
subsequent studies. In the Virginia Adult Twin Study of
Psychiatric and Substance Use Disorders 14 SNPs from
GAD2 were first genotyped in 188 cases with internalizing
disorders (major depression, GAD, panic disorder, agora-
phobia, social phobia, or neuroticism personality trait) and
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the same haplotype were followed up by genotyping
additional 401 cases and 351 controls but the initial
finding was not replicated [40]. Another study, consisting
of anxiety disorder cases (N = 268), cases with major
depression (N = 541), and 541 healthy controls, tested
association to 18 SNPs within GAD2 [41]. One SNP
(rs8190646) significantly associated to major depression
(p = 0.00039). No association to anxiety disorders was
found. To mimic the phenotype of the original study
[38] association of these SNPs were also tested with
behavioral inhibition in 211 anxiety disorder cases, 202
cases with major depression, and 537 controls from
the same sample. Significant association to behavioral
inhibition was found in the subgroups of anxiety disorder
cases and healthy controls, but not to cases with major
depression or all groups combined. The contradictory
findings in these two larger studies may be explained
by several differences, such as phenotype definition
and ethnicity of the study participants. The large on-
going GWAS studies should inform whether GAD2
variants predispose to various anxiety disorders or other
psychiatric phenotypes.
Regulator of G-protein signaling 2 (Rgs2)
A more recent successful cross-species study concerns
the genetic background of emotionality. Initially, a linkage
to chromosome 1 was found by QTL mapping of DeFries
mouse strains [42], and the locus was fine mapped in
outbred mice [43]. This region contains the Rgs2 gene,
encoding a regulator of G protein signaling. To investigate
whether Rgs2 interacts with the functional variant, quantita-
tive complementation method was applied, and a small-
effect QTL contributing to behavioral variation in mice was
identified [44]. Furthermore, knock-out mice of Rgs2 show
increased anxiety-like behavior [45]. These results indicate
that Rgs2 regulate anxiety-like behavior in mice. To
study the involvement of variants in RGS2 in intermediate
phenotypes of human anxiety disorders Smoller et al.
studied a family based sample (119 families) of children
with behavioral inhibition, 744 unrelated adults who were
tested for extraversion and introversion personality traits,
and 55 unrelated adults tested with the emotional face
assessment during fMRI [46]. RGS2 SNPs associated with
childhood behavioral inhibition (haplotype p = 0.00003)
and introversion personality trait (p = 0.007-0.05 for single
SNPs, p = 0.038 for a haplotype) as well as increased activa-
tion of amygdala and insular cortex in response to watching
fearful faces. In another study, four SNPs within RGS2
showed some association to panic disorder (p = 0.02-0.05)
in a sample of 173 German cases and 173 controls [47].
Also, one SNP in RGS2 was associated to GAD in a sample
of 607 adults exposed to 2004 Florida hurricane (p = 0.026)
[48]. However, a recent study of 2661 individuals from theVirginia Adult Twin Study of Psychiatric and Substance
Use Disorders aiming to replicate the previous findings
failed to find association to three most consistently
associated SNPs from these previous studies [49]. Again
these discrepant results may be due to differences in the
phenotype definitions or ethnic background of the samples.
However, twin studies suggest that many of these pheno-
types share common risk factors [50], although it is not
clear how strongly they are expected to relate to specific
risk alleles and their effect size.
Peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha (Ppargc1a)
Hettema et al. [51] combined data from several sources
to identify and study 52 novel candidate genes for
anxiety-spectrum disorders. They started with using
strain distribution pattern analysis in heterogeneous
stock mice that differ in anxiety-like behavior [29]. They
then ranked these genes according to prior data including
1) extant linkage and knockout studies in mice, 2) a
meta-analysis of human linkage scans, and 3) a preliminary
human GWAS. Subsequently SNPs covering the nine
top-ranked regions containing 14 genes were genotyped
in a two-stage association study of subjects from the
Virginia Adult Twin Study of Psychiatric and Substance
Use Disorders chosen for high or low genetic loading
for anxiety-spectrum phenotypes. Several SNPs within
the transcriptional co-activator PPARGC1A associated
with the anxiety phenotype. Initially PPARGC1A was
discovered in the muscle cells and brown fat and
characterized as a transcriptional co-activator, which
stimulates mitochondrial biogenesis by increasing oxidative
phosphorylation and by enhancing oxidative respiration
[52]. Further studies indicated that PPARGC1A acti-
vates nuclear respiratory factor 1 (NRF1) and 2 (NRF2)
[53]. These two genes are linked to oxidative stress,
and involvement of oxidative stress in anxiety has been
suggested by human and rodent studies, as discussed
in recent reviews [54,55].
Gabra2, Oprm1 and TrkB in PTSD
Fear conditioning, a form of Pavlovian learning, has been
used to model some aspects of PTSD. Parker et al. used
an intercross of inbred mouse strains C57BL/6J x DBA/2J
to identify, and an F8 advanced intercross line to fine-map,
QTL associated with fear conditioning [56]. Subsequently,
publicly available DNA sequence information and gene
expression data were used to identify candidate genes based
on the existence of non-synonymous coding polymor-
phisms and/or expression QTLs. Several candidate
genes previously implicated in PTSD in humans were
identified: gamma-aminobutyric acid receptor subunit
alpha-2 (Gabra2), opioid receptor-mu1 (Oprm1), and
neurotrophic tyrosine kinase (TrkB). GABRA2 modulates
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associated with PTSD in adult patients previously exposed
to child abuse [57]. OPRM1 has been linked with PTSD
through different levels of μ-opioid receptor binding
potential in a sample consisting of patients with PTSD
(N = 16) and controls with (n = 14) or without (n = 15)
combat exposure [58]. TRKB is a receptor for brain-
derived neurotrophic factor (BDNF). Carriers of the
Met allele of the BDNF Val66Met polymorphism show
impaired fear extinction and disturbed fronto-amygdala
activity [10]. In addition to these genes already linked to
PTSD, Parker et al. found several other genes associating
with fear conditioning in mice, and variants in the
homologous human genes should be investigated as
candidate genes for PTSD.
Gene expression profiling in brain tissue
Functional genomics experiments represent a data-driven
approach for identifying associations between a phenotype
and genes or gene networks. Based on the data, specific
hypotheses can be formulated and tested in vitro and
in vivo. Inbred mouse strains that differ in their innate
anxiety levels have been used to identify gene expression
patterns that correlate with behavioral phenotypes across
a number of strains [59-61]. Fernandes et al. investigated
gene expression in the hippocampus of eight inbred
strains, which differ in many behavioral phenotypes, and
identified 200 genes showing strain differences. The
strongest genetic correlation with a phenotype was found
for catechol-O-methyl transferase (Comt), a gene previously
associated with aggressive behavior [59]. A panel of eight
inbred strains was used by Letwin et al. to identify
strain and brain region-specific expression differences
in five brain regions. They identified several glutamatergic
signaling pathway-related genes correlating with anxiety-
like behavior [61]. We investigated gene expression differ-
ences in seven brain regions of six inbred mouse strains
that differ in their innate anxiety levels [60]. We correlated
gene expression patterns from seven brain regions, known
to regulate some aspects of anxiety, with behavioral
anxiety-measures and identified genes with an expression
pattern that correlates with anxiety-like behavior. We then
functionally verified by lentivirus-mediated gene transfer
(overexpression and silencing by RNAi) that two genes,
glyoxalase 1 (Glo1) and glutathione reductase (Gsr) regulate
anxiety in mice [60]. Since Glo1 has been identified by sev-
eral studies using various approaches, it is discussed further
in the next section. The challenge with the translation of
the gene expression findings to human anxiety disorders is
the poor availability of good quality post mortem brain
samples. Another approach is to test if DNA variants in the
homologous human genes confer predisposition to anxiety
disorders, but since a large number of the gene expression
changes are expected to be reactive rather than causal,this approach may work better on a pathway than single
gene level.
As a translational step we tested whether genetic variants
in 13 genes shown to be differentially expressed between
anxious and non-anxious mouse strains predispose humans
to anxiety disorders. We carried out a genetic association
analysis in a Finnish population-based Health 2000 Cohort
consisting of 321 cases and 653 matched controls. Variants
in six genes (CDH2, ALAD, PSAP, EPB41L4A, DYNLL2,
and PTGDS) showed some evidence (p < 0.01) for asso-
ciation to anxiety disorders [62]. Interestingly, Cdh2 was
recently shown to confer susceptibility to compulsive
behavior in dogs [63].
Glo1 has been identified through various approaches
Glo1 was one of the genes identified through gene
expression profiling in inbred strains having a higher
expression level in anxious strains [60]. In the same
study, its overexpression in the cingulate cortex by
lentivirus-mediated gene transfer resulted in increased
anxiety-like behavior, while inhibition by overexpression
of an shRNA decreased anxiety-like behavior. Glo1 was
independently identified through a genome-wide search
for copy number variants (CNVs) in inbred strains [64]. It
was shown that the difference in Glo1 expression between
inbred mouse strains is due to a CNV, the presence of
which correlates positively with anxiety-like behavior. To
show a causal relationship between the CNV and anxiety-
like behavior Distler et al. generated BAC transgenic mice
expressing different copy numbers of Glo1 [65]. The mice
with several copies have increased anxiety-like behavior, as
expected. GLO1 is a detoxification enzyme, which together
with glyoxalase 2 converts cytotoxic methylglyoxal (MG)
to non-toxic form [66,67]. When exploring the molecular
mechanism of GLO1 underlying anxiety behavior Distler
et al. found that overexpression of Glo1 reduces MG level
in the brain. Moreover, they showed that MG is an agonist
of GABAA receptors, and therefore reduced levels of MG
decrease GABAA receptor activation [65]. This finding
conforms well to the known involvement of GABAA
receptors in the regulation of anxiety. Interestingly, two
proteomics studies have also linked GLO1 with anxiety-
like behavior. According to these studies GLO1 is
down-regulated in the brain of two separate mouse strains
selectively bred for high anxiety behavior compared
to their respective low-anxiety strains [68,69], a finding
contradictory to the findings in the inbred strains. This sur-
prising difference is likely due to other alleles contributing
to the anxiety phenotype in these models and other factors
related to the selective breeding of the strains, including
differences in initial allelic frequencies, linked alleles, and
drift before or during inbreeding [70]. More detailed discus-
sion on the role of GLO1 in behavioral phenotypes is found
in an excellent recent review [70].
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in humans. Patients with major depression or bipolar
disorder show reduced GLO1 expression when in de-
pressive state, but not during remission [71]. However,
cholecystokinin-tetrapeptide (CCK-4), which is used to
induce panic attacks, did not have an effect on GLO1
mRNA levels in peripheral blood cells of 23 healthy
volunteers [72]. In schizophrenia patients, rare genetic
variants in GLO1 have been associated with decreased
enzyme activity and increased carbonyl stress [73].
Genetic association studies have been carried out in
anxiety disorders. A common Ala111Glu substitution
in GLO1, responsible for conformational change and
decreased enzymatic activity, was investigated in 162
panic disorder patients and 288 matched controls from the
Italian population [74]. Although there was no evidence of
association to the overall diagnosis, some evidence was
found for association with panic disorder without agora-
phobia (N = 61 patients, p = 0.015). Similarly, Donner et al.
failed to find strong evidence for association with this SNP
and anxiety disorders in the Finnish population (p = 0.021)
[62]. This functional SNP therefore does not seem to play a
major role in the predisposition to anxiety disorders. Larger
genetic studies are needed to find out whether other
common or rare variants within GLO1 are involved in
the etiology of anxiety disorders.
Proteomic studies in mouse models
Altogether three proteomic studies have been carried
out in bidirectionally bred mouse strains for high or low
levels of anxiety. In the HAB/LAB mouse model several
proteins have been identified, including GLO1, discussed
already in detail above [69], and another interesting en-
zyme, enolase-phosphatase [75]. In a different bidirectional
mouse model of anxiety-like behavior Szego et al. identified
alterations in serotonin receptor-associated proteins [69].
Recent proteomic analysis of rat hippocampus after psycho-
social stress revealed 21 differently expressed proteins. They
were involved in various cellular functions, including signal
transduction, synaptic plasticity, cytoskeleton remodeling
and energy metabolism [76].
Since the proteomics-based methods are developing
with fast pace, it is expected that they will in the near future
reveal biomarker panels to be used in biological diagnostics
of psychiatric disorders, in addition to shedding light to the
neurobiological mechanisms regulating anxiety.
Conclusions
Because of their high prevalence, anxiety disorders impose
high social and economic burden. Integration of data from
several approaches is needed to understand the molecular
mechanisms that regulate anxiety, and to develop novel
pharmacological treatments. Genome-wide approaches to
identify regulators of anxiety-like behavior in animal modelswill greatly complement the ongoing GWAS efforts in
human anxiety disorders. There are two major advantages
in using mouse models compared to human patient
samples. Since environmental factors can be controlled for,
or specifically administered in animal models, the power to
detect small genetic effects is likely better in animal models
compared to human cohorts. Stress, especially in child-
hood, is a well-established risk factor for anxiety disorders,
and several mouse models for childhood stress have been
recently developed. These should be investigated in several
inbred genetic backgrounds, to identify gene-environment
interactions in controlled circumstances. Another benefit of
using animal models is the ability to harvest brain tissue at
any time point. This allows taking advantage of unbiased
genome-wide and proteome-wide identification of genes
that regulate anxiety. With mRNA-seq and small RNA-seq
it is now possible to identify all expressed genes from a
given tissue, at different time points. Bioinformatic inte-
gration of this information can then be used to identify
dynamic gene regulatory networks, instead of single genes.
Optogenetic manipulation of specific cell types, combined
with behavioral and gene expression analysis will help
to detect yet more specific circuits underlying anxiety
behavior. This approach will require development of
better methods to dissect specific cell types and to carry
out RNA-seq from very small amounts of RNA.
Results from the animal models should be used to
formulate and test specific hypotheses in humans, using
genetic and imaging approaches. The progress of the
translation has been hindered by the relatively small size
of well-characterized anxiety disorder cohorts, as can be
seen with examples given above. Also, anxiety disorders
as a group are phenotypically heterogeneous and it is
not expected that all genetic findings replicate across
all phenotypes. Integration of results from human gen-
etic and imaging approaches with mouse genetic and
functional studies will be essential to understand the
neurobiological basis of anxiety disorders, a prerequisite
for targeted therapies.Abbreviations
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